Arcuri LJ, Lerner D, Tavares RCBDS. Lower levels of cyclosporine between days 0 and +21 may reduce later relapses without increasing graft-versus-host disease in children and adolescents with acute lymphoblastic leukemia who undergo myeloablative TBI-based allogeneic hematopoietic cell Eur J Haematol 2022 May 9. doi: 10.1111/ejh.13787.
PMID: 35532300